EchoNous vs Eyenuk
Kosmos is a handheld ultrasound with AI for bladder volume, ejection fraction, Doppler gate placement and FAST views. The vendor says Kosmos Plus costs under $20k, billing basis not stated, and carries a five-year warranty. It exports DICOM, supports a modality worklist through a DICOM profile, and the home page claims SOC 2 Type II. A 2024 study had oncology staff check cardiac function during chemotherapy with it, which makes a cancer center one fit.
EyeArt grades retinal photographs for diabetic retinopathy, and the vendor says the report needs no physician overread. The home page gives 96% sensitivity and 88% specificity for more than mild disease, while a 2023 release on trial NCT04984200 gives 94.4% and 91.1%. openFDA lists two records under product code PIB, K200667 in August 2020 and K223357 in June 2023, and the vendor says its clearances cover the Canon CR-2 AF, CR-2 Plus AF and Topcon NW400 cameras. The vendor says it integrates with Epic and other EHRs. Primary care clinics and screening programs are the buyers.
Different people hold the two devices: a bedside clinician with a probe for Kosmos, a screening program's operator with a retinal camera for EyeArt.
Radiology · Reviewed November 2, 2026
When to pick each one
EchoNous
- Kosmos Plus under $20k, vendor says, billing basis not stated
- Five-year warranty stated on the FAQ
- SOC 2 Type II and DICOM modality worklist
Eyenuk
- Vendor says no physician overread for diabetic retinopathy grading
- openFDA lists K200667 and K223357 under code PIB
- Integrated with Epic per the vendor
Score
Each row shows points earned of points available under the published rubric.
EchoNous
78of 100
Eyenuk
71of 100
| Dimension | EchoNous | Eyenuk | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 10 / 10 | 10 / 10 | 0 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 18.2 / 18.2 | 18.2 / 18.2 | 0 |
| RCT / meta-analysis / systematic review | 7.8 / 7.8 | 7.8 / 7.8 | 0 |
| Funding & adoption signal | 3 / 12 | 3 / 12 | 0 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 6 / 6 | 0 / 6 | +6 |
Scroll horizontally to see every column.
Pricing
EchoNous
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. The vendor says Kosmos Plus costs less than $20k. |
Eyenuk
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Evidence
EchoNous
FDA decisions
K242321 (opens in new tab)510(k)2025-04-25
Kosmos
K233826 (opens in new tab)510(k)2024-08-29
Kosmos
K212100 (opens in new tab)510(k)2021-08-06
Kosmos
K193518 (opens in new tab)510(k)2020-03-26
KOSMOS
Peer-reviewed
5 PubMed records name EchoNous.
- Army Medic Performance in Trauma Sonography: The Impact of Artificial Intelligence Assistance in Focused Assessments With Sonography in Trauma-A Prospective Randomized Controlled Trial. (opens in new tab)
- Point-of-care AI-enhanced novice echocardiography for screening heart failure (PANES-HF). (opens in new tab)
- Validation of a hand-held ultrasound device in the evaluation of aortic stenosis. (opens in new tab)
Eyenuk
FDA decisions
K223357 (opens in new tab)510(k)2023-06-16
EyeArt v2.2.0
K200667 (opens in new tab)510(k)2020-08-03
EyeArt
Peer-reviewed
5 PubMed records name Eyenuk.
- Diagnostic Accuracy of the EyeArt Artificial Intelligence System for Diabetic Retinopathy: A Systematic Review and Meta-Analysis. (opens in new tab)
- A pilot cost-analysis study comparing AI-based EyeArt® and ophthalmologist assessment of diabetic retinopathy in minority women in Oslo, Norway. (opens in new tab)
- [Use of Artificial Intelligence in Diabetic Retinopathy Screening: Experience in a Health Service in Santiago, Chile]. (opens in new tab)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | EchoNous | Eyenuk |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | 2016 | n/a |
| HQ | US | US |
Scroll horizontally to see both columns.
Common questions
Open the full radiology comparison
Acute-care triage, mammography screening, CCTA plaque analysis, mobile MRI. 30+ FDA-cleared platforms across stroke, oncology, cardiac. Enterprise sales only — we compared what's deployed where.


